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Abstract: 
No published studies have compared the outcome after transcatheter aortic valve implantation (TAVI) with the 
outcome in the general population. Thus, it is unknown whether TAVI restores normal life expectancy and 
stroke risk. Furthermore, despite the increasing use of TAVI, only little is known about the temporal trends for 
TAVI regarding patient characteristics and outcomes. We identified all Danish patients treated with TAVI from 
2006-2014 (n=1,631) and 9,737 general population controls matched by sex, age and comorbidity. The primary 
endpoint was a composite endpoint of all-cause mortality and stroke. During the first 90 days, the risk of the 
combined endpoint, the stroke risk and mortality were significantly higher among TAVI patients compared to 
controls (9.4%, 7.5% and 2.5% respectively in TAVI patients compared to 2.0%, 1.6% and 0.5% in controls). 
After 90 days, there were no differences (adjusted mortality rate ratio, stroke rate ratio and mortality or stroke 
rate ratio 0.92 (0.79-1.06), 1.32 (0.98-1.78), and 1.00 (0.90-1.10), respectively). During the study period, there 
were small changes in the characteristics of patients treated by TAVI; however, more patients were treated by 
transfemoral access; fewer needed  blood transfusions, hospital stays were shorter, and the overall mortality 
rate decreased. In conclusion, 90 days post-TAVI, the stroke risk and mortality of the TAVI patients were 
comparable to the stroke risk and mortality of the general population. Over time, the patient risk profiles have 
remained largely unchanged; however outcomes have improved substantially including lower short- and long-
term mortality. 
 
 
 
 
Keywords: TAVI, mortality, stroke, temporal trends. 
Page 2 of 21
3 
 
Aortic valve stenosis (AS) is the most common valvular heart disease in the Western World. If treated 
conservatively, patients with symptomatic severe AS have a poor prognosis1. During the last decade, 
transcatheter aortic valve implantation (TAVI) has become a widely accepted treatment modality which is now 
the treatment of choice in inoperable severe AS patients and as an alternative to surgery in patients with 
higher surgical risk2, 3. Lately, TAVI has also been shown to be a good alternative to surgical aortic valve 
implantation (SAVR) in intermediate-risk patients with outcomes after 2 years being comparable to SAVR4-6. A 
few studies have compared the outcome after SAVR with the general population7, 8. However, to our 
knowledge no published studies have compared the outcome after TAVI with the outcome in the general 
population using individual level data. Furthermore, despite the widespread use of TAVI as a well-established 
treatment modality, only little is known about the temporal trends for TAVI regarding patient characteristics 
and outcomes. The few existing studies indicate that TAVI is increasingly used in low-risk patients and that the 
outcome after TAVI is improving9-11. We therefore conducted a nationwide follow-up study comparing the 
mortality and stroke risk among all Danish patients treated with TAVI with the general population. Further, we 
evaluated the temporal trends in the patient and treatment characteristics, as well as short- and long term 
outcome, after TAVI.  
 
METHODS 
We conducted a national population-based historical follow-up study in Denmark with approximately 
5.7 million inhabitants. The National Health Service provides tax-supported healthcare, guaranteeing 
unfettered access to medical care. All TAVI procedures are performed at four public hospitals in Denmark. The 
Danish Civil Registration System keeps records of sex, date of birth, and vital status. The records carry a 10-digit 
civil registration number assigned to every Danish citizen and used in all Danish registers, enabling 
unambiguous record linkage between them. The Web-PATS (Eastern Denmark) and the Western Denmark 
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Heart Registry (WDHR) collects detailed data related to patients and procedures for all interventions carried 
out in the 4 interventional centers performing TAVI in Denmark (Rigshospitalet, Copenhagen; Odense 
University Hospital; Aarhus University Hospital ; and Aalborg University Hospital). Reporting to the registries is 
mandatory and data quality is ensured by systematic validation procedures and random spot-checks of data 
after entry12. We identified all Danish patients treated with TAVI from 2006-2014 (n=1,631). Each patient was 
matched by sex and age with 40 individuals from the general population who were alive on the date of the 
associated patient’s TAVI procedure. These controls were sampled using the Danish Civil Registration system. 
After computing the Charlson comorbidity index as a measure of comorbidity (described in next section), 
patients and controls were also matched by this index. The total number of controls was 9,737. The median 
number of controls for each TAVI patient was 8. It was not possible to identify at least one control for 106 TAVI 
patients (6.5% of all patients). We obtained data regarding baseline patient characteristics and all procedure-
related data from the Web-PATS and the WDHR. The Danish National Patient Registry collects data for all 
hospitalisations at Danish hospitals, including dates of admission and discharge, and discharge diagnoses. 
Based on the last 10 years of hospitalization history for each patient and control, we computed the Charlson 
comorbidity index score13, which was adapted for use with hospital discharge registry data14. We defined three 
levels of comorbidity: a score of 0 (“low”); a score of 1-2 (“moderate comorbidity”); and a score >2 (“high 
comorbidity”). The Danish Transfusion Database is a national registry monitoring the use of all blood 
components. We obtained information regarding the types and number of blood components administered 
from the day of the TAVI procedure and the following eight days. We obtained data regarding the use of 
cardiovascular drugs from the Danish Medicines Agency’s Register of Medicinal Product Statistics, a national 
prescription registry that contains information on all redeemed prescriptions for reimbursable drugs dispensed 
from all pharmacies in Denmark (Data available until the end of 2015). The information includes type of drug 
and the date dispensed. We identified all prescriptions for aspirin, clopidogrel, statins, diuretics, angiotensin 
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converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, and selective and non-selective β-
blockers filled from hospital discharge until the end of follow-up. In the comparison between patients treated 
with TAVI and the general population, the primary endpoint was a composite of all-cause mortality and stroke 
(ICD-10 I61, I63-64) after 90 days and 2 years. In the evaluation of the temporal trends, the primary endpoint 
was a composite of all-cause mortality and stroke at 30 days, one year, and two years. Data on stroke was 
obtained from the Danish National Patient Registry (data available until the end of 2015) and deaths were 
ascertained from The Danish Civil Registration System (data available until the end of 2016). The patients were 
censored at the time of death or followed until the end of 2016. Data regarding stroke; and thus, the 
composite endpoint were only available until the end of 2015. The mean follow-up time was 2 years. We used 
the Cox proportional hazards regression model to compute crude and adjusted hazard ratios (HR) and 95% 
confidence intervals (CI) for the endpoints. The hazards were not proportional throughout the follow-up period 
when comparing patients and general population controls; therefore, we estimated the HR within the periods 
during which the proportionality assumption held in these analyses (i.e., 0-90 days and >90 days-2 years); and 
we used a Cox model with delayed entry using age as the time scale. We adjusted for comorbidity as a 
continuous variable to reduce residual confounding. The general population controls served as the reference. 
The analyses were repeated after stratifying by treatment year of the TAVI patient. When evaluating the 
temporal trends, we compared baseline characteristics using the Student’s t-test for continuous variables and 
the χ2-test for categorical variables. We used the Cox proportional hazards regression model to compute crude 
and adjusted HR and 95% CI for the endpoints. The patients were divided into three groups comparable in size 
according to the year of treatment (2006-2010, 2011-2012 and 2013-2014). The patients treated 2006-2010 
served as the reference in all analyses and all tests of significance were two-tailed with p<0.05 considered 
statistically significant. Data regarding stroke and thus the combined endpoint after 2 years were only available 
for patients treated until the end of 2013. Analyses regarding these endpoints were based on patients treated 
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between 2006 and 2013. The number of patients with complete data for all variables was 672 (41%). However, 
for the individual variables, only a minor proportion of the patients had missing data (0.0%-10%). The 
exceptions were the Logistic EuroSCORE (37% missing) and atrial fibrillation (45% missing). We used multiple 
imputation to impute missing values for all variables. Besides all measured variables, we included the event 
indicator and the Nelson-Aalen estimator of the cumulative hazard to the survival time in the imputation 
model15. Analyses were conducted on 20 imputed datasets and the results combined using Rubin’s rules16. Sex, 
age, and comorbidity were forced into all of the multivariable analyses. To optimize the precision of the risk 
estimation, we used the change-in-estimate method when selecting additional covariates to be included17. 
Covariates were selected based on a relative change of more than 10% in the estimated exposure effect. A 
family history of coronary artery disease, hypertension, peripheral artery disease, and site of implantation were 
in this way identified as possible confounding factors and included in the final multivariable model. The 
analyses were repeated after stratifying by sex and age (≤70 years, 70-80 years, >80 years). We analyzed data 
using Stata version 14.0 (StataCorp, College Station, TX, USA) software. Our study was approved by the Danish 
Data Protection Agency (journal number 2007-58-0010). 
 
RESULTS 
Table 1 and Figure 1 present mortality rates and cumulative mortality curves of the patients treated by 
TAVI and the sex-, age- and comorbidity matched general population controls. The rate of the composite 
endpoint, the mortality rate, and the stroke rate within 90 days were significantly higher among TAVI patients 
compared to controls. The adjusted mortality or stroke rate ratio, mortality rate ratio, and stroke rate ratio 
were significantly higher among patients compared to controls. After 90 days, there were no differences in the 
mortality rates or stroke rates compared with the general population. No substantial differences were 
observed when the analyses were stratified according treatment year of the TAVI patient (data not shown). 
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Table 2 shows the patient characteristics according to year of treatment. Compared to the patients treated 
from 2006-2010 more patients treated from 2011-2012 and from 2013-2014 had hypertension, chronic 
obstructive pulmonary disease, and atrial fibrillation whereas fewer were previous or active smokers, fewer 
had a family history of coronary artery disease, and fewer had a history of percutaneous coronary intervention 
or heart surgery. Fewer were treated with diuretics and aspirin prior to the TAVI procedure. Although not 
statistically significant, there was a trend towards higher preoperative ejection fraction, more peripheral artery 
disease and fewer patients with previous myocardial infarction over time. The treatment characteristics 
according to year of treatment are shown in table 3. Over time, more femoral procedures and fewer trans-
apical procedures were performed. There were statistically significant differences in the valve type and valve 
size used in the three periods but no obvious trend over time was observed. Compared to the patients treated 
from 2006-2010 patients treated from 2011-2012 and from 2013-2014 had significantly shorter hospital stays. 
When comparing the use of medications after 1 year, fewer patients treated from 2013-2014 received aspirin 
compared to patients treated from 2006-2010 and 2011-2012. Over time, there was a significant decline in the 
proportion of patients treated with aspirin after 2 years. No differences in treatment with clopidogrel, β-
blockers, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, statins, and diuretics after 
1 year and 2 years were found (table 4). The cumulative risk of the combined endpoint after 1 year were 20.3%, 
19.4%, and 14.9% among patients treated from 2006-2010, 2011-2012, and 2013-2014 respectively. The 
corresponding HR for patients treated from 2013-2014 compared to patients treated from 2006-2010 was 0.71 
(0.53-0.95). Similar results were found after 30 days and although there was a clear trend towards similar 
results after 2 years, the differences were not statistically significant. The differences were mainly explained by 
differences in the cumulative mortality which reached statistical significance at all points in time, 2 year 
HR=0.75 (0.57-0.97). When comparing the cumulative risk of stroke, no differences were found at any point in 
time. Adjustment for differences in baseline characteristics did not change the results. When comparing 
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patients treated from 2006-2010 and patients treated from 2011-2012 no differences were found in any of the 
endpoints at any point in time. Table 5 shows the proportion of complications within 30 days. The proportion 
of patients receiving blood transfusions within 8 days after the TAVI-procedure was statistically significantly 
lower in the patients treated from 2011-2012 and 2013-2014 compared to patients treated from 2006-2010. 
There was no trend over time regarding the proportion of pacemaker implantations. However, significantly 
more patients treated between 2011 and 2012 had a pacemaker implanted compared to patients treated from 
2006-2010 and from 2013-2014. We found no changes in the need for vascular surgery and treatment for 
haemopericardium. No substantial differences were observed when the analyses were stratified according to 
sex and age (data not shown). 
 
DISCUSSION  
Our study presents the patient characteristics, treatment characteristics, and outcomes in all the 
patients treated with TAVI in Denmark from the first implantation in 2006 and until 2014.  The study has 
several important findings: (1) Beyond 90 days post-TAVI, the mortality and stroke rates of the patients were 
comparable to that of the general population; (2) there has been little change in the characteristics of patients 
treated by TAVI in Denmark from 2006 to 2014; (3) less invasive operative techniques have been widely 
adopted, i.e., more patients treated by transfemoral access; (4) outcomes have improved over time with a 
decrease in the need for blood transfusions,  shorter hospital stays,  and lower short- and longterm all-cause 
mortality. To the best of our knowledge, no published study has compared the prognosis after TAVI with the 
prognosis in the general population. Two previous studies have compared the quality of life and the long term 
survival between patients treated with SAVR and the general population. The studies showed comparable 
outcomes after SAVR compared to the general population7, 8. However, these studies did not have individual 
level data regarding the general population. Rather they compared their patients with expected values 
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regarding the quality of life and expected mortality using life time tables. In contrast to this, we were able to 
match our patients with a background population according to sex, age, and comorbidity. We found 
significantly higher mortality and stroke rates in the first 90 days after the TAVI-procedure. However, after the 
perioperative period, the mortality and stroke rates in the TAVI-patients were comparable to the mortality and 
stroke rates in the background population. The latter is positive and reassuring information which can be useful 
when informing patients about the prospects after TAVI. The limited changes over time in the characteristics of 
TAVI-patients in our study  is in accordance with a previous study of all TAVI procedures performed in the 
United Kingdom from 2007-2012. The authors found a shift toward the treatment of patients with lower left 
ventricular ejection fraction. However, this was not associated with a change in the calculated Logistic 
EuroSCORE10. In contrast, two recent studies based on Israeli and French registries showed that over time TAVI 
is used in lower risk patients with less comorbidity. Both studies found a significant decrease in the mean 
logistic EuroSCORE / STS Risk Score during the study period9, 11. The adoption of less invasive access techniques 
in recent years is also in accordance with previous studies9-11. One study however, also found an increase in the 
use of the direct aortic approach, which we could not confirm in our study10. We found no changes in the need 
for vascular surgery. This corresponds with the findings of some9, 11 but not all10 previous studies. However, we 
obtained these data from the Danish National Patient Registry, and the validity of these data is known to be 
high18. We found a low incidence of vascular complications of only 1.7-2.4% compared to 2.6-5.5% in one 
study10 and up to 15% in a second study11. This might indicate that there is a problem with validity of these 
data in our registries. However, our data regarding blood transfusions are very precise. These data show a 
statistically significant decrease in the need for blood transfusions during the perioperative period. One of the 
most obvious findings of our study was the marked decrease in the mean length of hospital stay from 10.2 days 
to 6.9 days in the earliest and the latest period respectively. Similar results have been found in all three 
previous studies9-11. We found lower cumulative risk of the combined endpoint after TAVI in patients treated 
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from 2013-2014 when comparing with earlier periods, although the changes were only significant after 1 year. 
This trend was mainly explained by a lower cumulative mortality over time. The changes in mortality were 
statistically significant after 30 days, 1 year and 2 years when comparing patients treated in the earliest and 
latest period. These results are also in accordance with the previous studies and the cumulative mortality in our 
study corresponds well to the previously found cumulative mortality9-11. However, in one of the studies, the 
differences in mortality were no longer statistically significant after adjustment for differences in baseline 
patient characteristics9. In the French study11, they also found a decrease in the rate of stroke, which we did 
not find. The main strengths of our study are the relatively large number of patients, the long follow-up period, 
the prospective, population-based design, and the possibility of unambiguous individual-level linkage between 
public data sources, which provided detailed information on patient characteristics, treatments, and use of 
medications, and allowed complete follow-up, minimising the risk of selection bias. The Danish Civil 
Registration System and the Danish National Patient Registry made it possible to identify matched controls 
from the background population, which is unique. We used hospital discharge diagnoses, which may not 
always be accurate. However, the validity of the diagnoses included in this study were high (e.g., positive 
predictive values reported to be at least 80%)18-21. We did not take into account the percentage of patients who 
already had a pacemaker before the TAVI procedure. Thus, we have probably underestimated of the real rate 
of new pacemaker implantations. We controlled for a wide range of factors possibly affecting outcome; yet, 
due to the observational study design, we cannot exclude the possibility that confounding factors still 
influenced the results. In conclusion, after 90 days post-TAVI, the mortality and stroke rates of the TAVI 
patients were comparable to the mortality and the stroke rates of the general population. During the period 
from 2006-2014, the baseline patient risk profiles have remained largely unchanged. However, an increased 
use of transfemoral access has been adopted, fewer patients need blood transfusions peri-procedurally, the 
TAVI patients require a shorter hospital stays and the cumulative mortality has decreased over time.  
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Figure legends 
 
 
Figure 1: Cumulative incidence curves of the combined endpoint, mortality, and stroke in patients treated with 
transcatheter aortic valve implantation and sex, age, and comorbididy matched general population controls. 
Landmark analysis discriminating between events occurring before (A) and after 90 days of follow-up (B) 
Table 1. Mortality rates and mortality rate ratios of the patients treated with transcatheter aortic valve 
implantation (TAVI) vs. age, sex and comorbidity matched controls from the general population. n/N (%) 
 Mortality or stroke Mortality Stroke 
 
 
 
 
0-90 days 
TAVI 153/1631 (9.4 %) 123/1631 (7.5 %) 40/1631 (2.5 %) 
General population 197/9737 (2.0 %) 160/9737 (1.6 %) 46/9737 (0.5 %) 
 
Mortality / incidence 
rates*  
TAVI vs.  
general population 
 
 
 
408.2 (348.4-478.3) 
82.5 (71.8-94.9) 
 
 
 
322.9 (270.6-385.3)  
67.3 (57.6-78.5) 
 
 
 
101.4 (74.4-138.2)  
19.2 (14.4-25.6) 
 
Adjusted mortality rate 
ratios†   
(95% confidence 
interval) 
 
 
3.40 (2.75-4.21) 
 
 
3.17 (2.48-4.06) 
 
 
4.31 (2.77-6.71) 
 
 
 
 
90 days - 2 years 
TAVI 273/1478 (18.5 %) 232/1508 (15.3 %) 58/1478 (3.9 %) 
General population 1196/9540 (12.5 %) 1044/9577 (10.9 %) 227/9540 (2.4 %) 
 
Mortality / incidence 
rates*  
TAVI vs.  
general population 
 
 
 
116.6 (103.5-131.3) 
76.3 (72.1-80.7) 
 
 
 
94.9 (83.4-108.0) 
65.8 (61.9-69.9) 
 
 
 
21.2 (16.4-27.5)  
13.5 (11.9-15.4) 
 
Adjusted mortality rate 
ratios†   
(95% confidence 
interval) 
 
 
1.00 (0.90-1.10) 
 
 
0.92 (0.79-1.06) 
 
 
1.32 (0.98-1.78) 
*per 1000 person years; †Mortality rate ratio adjusted for Charlson comorbidity score index. 
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Table 2. Baseline characteristics of patients treated with transcatheter aortic valve implantation according to 
treatment year. n/N (%) 
Variable 2006-2010 
(N=395) 
2011-2012 
(N=546) 
2013-2014 
(N=690) 
Total 
(N=1631) 
Men 194/395 (49.1 %) 286/546 (52.4 %) 359/690 (52.0 %) 839/1631 (51.4 %) 
Age (years) 
<70  
70-80  
80-90  
>90  
 
33/395 (8.4 %) 
120/395 (30.4 %) 
226/395 (57.2 %) 
16/395 (4.1 %) 
 
34/546 (6.2 %) 
220/546 (40.3 %) 
264/546 (48.4 %) 
28/546 (5.1 %) 
 
57/690 (8.3 %) 
229/690 (33.2 %) 
373/690 (54.1 %) 
31/690 (4.5 %) 
 
124/1631 (7.6 %) 
569/1631 (34.9 %) 
863/1631 (52.9 %) 
75/1631 (4.6 %) 
Charlson comorbidity 
index 
0 
1-2 
≥3 
 
 
102/395 (25.8 %) 
166/395 (42.0 %) 
127/395 (32.2 %) 
 
 
142/546 (26.0 %) 
235/546 (43.0 %) 
169/546 (31.0 %) 
 
 
170/690 (24.6 %) 
296/690 (42.9 %) 
224/690 (32.5 %) 
 
 
414/1631 (25.4 %) 
697/1631 (42.7 %) 
520/1631 (31.9 %) 
Body mass index (kg/m2) 
<20 
20-25 
25-30 
>30 
 
28/333 (8.4 %) 
129/333 (38.7 %) 
128/333 (38.4 %) 
48/333 (14.4 %) 
 
35/524 (6.7 %) 
175/524 (33.4 %) 
206/524 (39.3 %) 
108/524 (20.6 %) 
 
58/632 (6.7 %) 
333/632 (37.0 %) 
325/632 (33.7 %) 
210/632 (22.6 %) 
 
105/1489 (7.1 %) 
538/1489 (36.1 %) 
547/1489 (36.7 %) 
299/1489 (20.1 %) 
Hypertension 238/381 (62.5 %) 361/533 (67.7 %) 488/671 (72.7 %) 1087/1585 (68.6 %)* 
Dyslipidemia 192/383 (50.1 %) 285/538 (53.0 %) 379/678 (55.9 %) 856/1599 (53.5 %) 
Diabetes mellitus 63/379 (16.6 %) 102/536 (19.0 %) 139/678 (20.5 %) 304/1593 (19.1 %) 
Peripheral artery disease 64/393 (16.3 %) 97/545 (17.8 %) 135/686 (19.7 %) 296/1624 (18.2 %) 
Cerebrovascular disease 40/393 (10.2 %) 67/545 (12.3 %) 90/689 (13.1 %) 197/1627 (12.1 %) 
Chronic obstructive 
pulmonary disease 
 
67/393 (17.1 %) 
 
105/545 (19.3 %) 
 
163/688 (23.7 %) 
 
335/1626 (20.6 %)* 
Atrial fibrillation 75/211 (35.6 %) 158/317 (49.8 %) 211/371 (56.9 %) 444/899 (49.4 %)* 
Family history Coronary 
artery disease 
 
177/361 (49.0 %) 
 
149/483 (30.9 %) 
 
214/616 (34.7 %) 
 
540/1460 (37.0 %)* 
Smoking, Active or 
previous 
 
203/352 (57.7 %) 
 
231/519 (44.5 %) 
 
329/647 (50.9 %) 
 
763/1518 (50.3 %)* 
Previous myocardial 
infarction 
 
69/386 (17.9 %) 
 
81/531 (15.3 %) 
 
96/673 (14.3 %) 
 
246/1590 (15.5 %) 
Previous percutaneous 
coronary intervention 
 
101/391 (25.8 %) 
 
126/530 (23.8 %) 
 
132/676 (19.5 %) 
 
359/1597 (22.5 %)* 
Previous heart surgery 122/393 (31.0 %) 135/545 (24.8 %) 158/685 (23.1 %) 415/1623 (25.6 %)* 
Left ventricular ejection 
fraction 
<30% 
 
 
33/343 (9.6 %) 
 
 
37/504 (7.3 %) 
 
 
48/625 (7.7 %) 
 
 
118/1472 (8.0 %) 
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30-45% 
>45% 
60/343 (17.5 %) 
250/343 (72.9 %) 
73/504 (14.5 %) 
394/504 (78.2 %) 
114/625 (18.2 %) 
463/625 (74.1 %) 
247/1472 (16.8 %) 
1107/1472 (75.2 %) 
Logistic EuroSCORE 15.8 (13.5-18.4 %) 15.5 (14.4-16.7 %) 15.0 (14.2-15.9 %) 15.2 (14.6-15.8 %) 
Preoperative medications: 
Aspirin 
Clopidogrel 
Βeta-blocker 
ACE-I / AT2 
Statins 
Diuretics 
 
298/355 (83.9 %) 
305/355 (85.9 %) 
218/355 (61.4 %) 
158/355 (44.5 %) 
237/355 (66.8 %) 
297/355 (83.7 %) 
 
400/496 (80.7 %) 
420/496 (84.7 %) 
299/496 (60.3 %) 
242/496 (48.8 %) 
320/496 (64.5 %) 
398/496 (80.2 %) 
 
468/657 (71.2 %) 
532/657 (81.0 %) 
411/657 (62.6 %) 
314/657 (47.8 %) 
416/657 (63.3 %) 
505/657 (76.9 %) 
 
1166/1508 (77.3 %)* 
1257/1508 (83.4 %) 
928/1508 (61.5 %) 
714/1508 (47.4 %) 
973/1508 (64.5 %) 
1200/1508 (79.6 %)* 
*p<0.05 
ACE-I: Angiotensin converting enzyme inhibitor; AT2: Angiotensin 2 receptor blocker 
 
Table 3. Treatment characteristics according to treatment year. n/N (%) 
Variable 2006-2010 
(N=395) 
2011-2012 
(N=546) 
2013-2014 
(N=690) 
Total 
(N=1631) 
Site of implant 
Femoral 
Apical 
Subclavian 
DirectAortic 
 
227/393 (57.8 %) 
157/393 (39.9 %) 
9/393 (2.3) %) 
0 
 
378/546 (69.2 %) 
150/546 (27.5 %) 
15/546 (2.7 %) 
3/546 (0.6 %) 
 
503/688 (73.1 %) 
171/688 (24.9 %) 
12/688 (1.7 %) 
2/688 (0.3 %) 
* 
1108/1627 (68.1 %) 
478/1627 (29.4 %) 
36/1627 (2.2 %) 
5/1627 (0.3 %) 
Valve type 
Core valve 
Portico 
Sapien (Cribier) 
Sapien XT 
Sapien 3 
 
197/381 (51.7 %) 
0 
74/381 (19.4 %) 
110/381 (28.9 %) 
0 
 
294/537 (54.7 %) 
0 
44/537 (8.2 %) 
199/537 (37.1 %) 
0 
 
278/681 (40.8 %) 
18/681 (2.6 %) 
18/681 (2.6 %) 
232/681 (34.1 %) 
135/681 (19.8 %) 
* 
769/1599 (48.1 %) 
18/1599 (1.1 %) 
136/1599 (8.5 %) 
541/1599 (33.9 %) 
135/1599 (8.4 %) 
Valve size (mm) 
≤23 
24-26 
≥27 
 
50/288 (17.4 %) 
146/288 (50.7 %) 
92/288 (31.9 %) 
 
56/508 (11.0 %) 
223/508 (43.9 %) 
229/508 (45.1 %) 
 
89/659 (13.5 %) 
277/659 (42.0 %) 
293/659 (44.5 %) 
* 
195/1455 (13.4 %) 
646/1455 (44.4 %) 
614/1455 (42.2 %) 
Peri-procedural blood 
transfusion 
167/395 (42.3 %) 163/546 (29.9 %) 161/690 (23.3 %) 491/1631 (30.1 %)* 
Length of stay (days) 10.2 (9.1-11.3) 8.1 (7.6-8.6) 6.9 (6.5-7.3) 8.1 (7.7-8.5)* 
Discharge day after 
Transcatheter aortic 
valve implantation 
3.  
4.  
5.  
 
 
 
23/380 (6.1 %) 
40/380 (10.5 %) 
62/380 (16.3 %) 
 
 
 
45/537 (8.4 %) 
115/537 (21.4 %) 
171/537 (31.8 %) 
 
 
 
106/687 (15.4 %) 
230/687 (33.5 %) 
319/687 (46.4 %) 
 
 
 
174/1604 (10.9 %)* 
385/1604 (24.0 %)* 
552/1604 (34.4 %)* 
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*p<0.05 
 
Table 4. Medical treatment characteristics according to treatment year. n/N (%) 
Variable 2006-2010 
(N=395) 
2011-2012 
(N=546) 
2013-2014 
(N=690) 
Total 
(N=1631†) 
Preoperative medications: 
 Aspirin 
 Clopidogrel 
 Βeta-blocker 
 ACE-I / AT2 
 Statins 
 Diuretics 
 
298/355 (83.9 %) 
305/355 (85.9 %) 
218/355 (61.4 %) 
158/355 (44.5 %) 
237/355 (66.8 %) 
297/355 (83.7 %) 
 
400/496 (80.7 %) 
420/496 (84.7 %) 
299/496 (60.3 %) 
242/496 (48.8 %) 
320/496 (64.5 %) 
398/496 (80.2 %) 
 
468/657 (71.2 %) 
532/657 (81.0 %) 
411/657 (62.6 %) 
314/657 (47.8 %) 
416/657 (63.3 %) 
505/657 (76.9 %) 
 
1166/1508 (77.3 %)* 
1257/1508 (83.4 %) 
928/1508 (61.5 %) 
714/1508 (47.4 %) 
973/1508 (64.5 %) 
1200/1508 (79.6 %)* 
Medical treatment 1 year 
 Aspirin 
 Clopidogrel 
 Βeta-blocker 
 ACE-I / AT2 
 Statins 
 Diuretics 
 
245/319 (76.8 %) 
104/319 (32.6 %) 
178/319 (55.8 %) 
148/319 (46.4 %) 
201/319 (63.0 %) 
244/319 (76.5 %) 
 
323/448 (72.1 %) 
125/448 (27.9 %) 
245/448 (54.7 %) 
205/448 (45.8 %) 
263/448 (58.7 %) 
317/448 (70.8 %) 
 
333/598 (55.7 %) 
187/598 (31.3 %) 
337/598 (56.4 %) 
269/598 (45.0 %) 
374/598 (62.5 %) 
409/598 (68.4 %) 
 
901/1365 (66.0 %)* 
416/1365 (30.5 %) 
760/1365 (55.7 %) 
622/1365 (45.6 %) 
838/1365 (61.4 %) 
970/1365 (71.1 %) 
Medical treatment 2 year 
 Aspirin 
 Clopidogrel 
 Βeta-blocker 
 ACE-I / AT2 
 Statins 
 Diuretics 
 
223/288 (77.4 %) 
35/288 (12.2 %) 
154/288 (53.5 %) 
143/288 (49.7 %) 
172/288 (59.7 %) 
207/288 (71.9 %) 
 
253/401 (63.1 %) 
75/401 (18.7 %) 
212/401 (52.9 %) 
187/401 (46.6 %) 
236/401 (58.9 %) 
278/401 (69.3 %) 
 
129/265 (48.7 %) 
41/265 (15.5 %) 
158/265 (59.6 %) 
117/553 (44.2 %) 
153/553 (57.7 %) 
172/553 (52.4 %) 
 
605/954 (63.4 %)* 
151/954 (15.8 %) 
524/954 (54.9 %) 
447/954 (46.9 %) 
561/954 (58.8 %) 
657/954 (68.9 %) 
*p<0.05 
†data regarding medical treatment after 2 years only available for patients treated until the end of 2013. Data 
regarding these endpoints based on patients treated in 2013 only (n=330) 
ACE-I: Angiotensin converting enzyme inhibitor; AT2: Angiotensin 2 receptor blocker 
 
Table 5. Complications in patients treated with transcatheter aortic valve implantation according to year of 
treatment. n(%) 
Complication 2006-2010 
(N=395) 
2011-2012 
(N=546)  
2013-2014 
(N=690)  
 
Bloodtransfusion within 7                  
days 
 
167 (42.3 %) 
 
163 (29.9 %) 
 
161 (23.3 %)* 
 
Pacemaker implantation 
 
61 (15.4 %) 
 
104 (19.1 %) 
 
95 (13.8 %)* 
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within 30 days 
 
Vascular surgery, femoral 
artery or infrarenal aorta 
within 30 days 
 
11 (2.8 %) 
 
9 (1.7 %) 
 
11 (1.6 %) 
 
Treated for 
haemopericardium within 
30 days 
 
3 (0.8 %) 
 
1 (0.2 %) 
 
1 (0.1 %) 
 
Surgery on thoracic aorta 
within 30 days 
 
0 
 
0 
 
0 
*p<0.05 
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